reports
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an...
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug Administration (FDA) for Lasix® ONYU (furosemide injection), a novel drug-device...
Cytokinetics Inc: 1 director
A director at Cytokinetics Inc sold 6,757 shares at 60.000USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Gran Tierra Energy Inc. Appoints New Director
Gran Tierra Energy Inc. Appoints New Director CALGARY, Alberta, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) is pleased to announce the appointment of Brad Virbitsky to the Company’s Board of Directors as an independent director, effective September 30, 2025. Mr. Virbitsky is a portfolio manager and partner at Equinox Partners LLC, a Connecticut-based investment firm with over 30 years of history in natural resources and emerging markets. Mr. Virbitsky has over a decade of experience working with managem...
PBF Energy Inc: 2 directors
Two Directors at PBF Energy Inc sold after exercising options/sold 110,000 shares at between 34.000USD and 34.134USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual...
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025 Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximaland Submaximal Exercise Capacity and Recovery Compared to Metoprolol 96-Week Analyses from FOREST-HCM SupportLong-Term Efficacy and Tolerability of Aficamten in Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data related to aficamten were presented in a Late Breaking Clinical Research...
Ligand Pharmaceuticals Inc: 1 director
A director at Ligand Pharmaceuticals Inc sold 10,000 shares at 170.809USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Cytokinetics Announces Call for Proposals for Its Eighth Annual Commun...
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 3rd, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program. The program will award five grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) a...
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic For...
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum SOUTH SAN FRANCISCO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 10:00 AM Eastern Time. Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at . The webcast replay will be archived on the Cytokinetics webs...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of common stock and 26,822 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in August and September 2025 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on...
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual...
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025 Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Clinical Research presentations and one poster presentation, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 taking place i...
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible S...
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Th...
Cytokinetics Announces Proposed Private Placement of $550.0 Million of...
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act...
Cytokinetics Presents New Data Related to Aficamten at the European So...
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%, Consistent with Expected Rates in Prediction Model of Patients with HCM; Simultaneous Publication in Heart Rhythm Longer-Term Data Presented Consistent with Previously Reported Safety Profile of Aficamten Company...
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the...
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that primary results from MAPLE-HCM (Met...
- Dave Nicoski
- Ross LaDuke
PBF PBF ENERGY INC. CLASS A
LEN LENNAR CORPORATION CLASS A
GPRE GREEN PLAINS INC.
GBCI GLACIER BANCORP INC.
FFIC FLUSHING FINANCIAL CORP.
DVN DEVON ENERGY CORPORATION
DECK DECKERS OUTDOOR CORPORATION
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CNO CNO FINANCIAL GROUP INC.
CBU COMMUNITY BANK SYSTEM INC.
BIIB BIOGEN INC.
BC BRUNSWICK CORPORATION
HP HELMERICH & PAYNE INC.
PVH PVH CORP.
TTC TORO COMPANY
HOG HARLEY-DAVIDSON INC.
WGO WINNEBAGO INDUSTRIES INC.
APLS APELLIS PHARMACEUTICALS
PRPL PURPLE INNOVATION
GRWG GROWGENERATION
DCOM DIME COMMUNITY BANCSHARES INC
APA APA CORPORATION
AMR ALPHA METALLURGICAL RESOURCES INC
BBWI BATH & BODY WORKS INC
CIVI CIVITAS RESOURCES INC
BORR BORR DRILLING LTD
MBC_w MASTERBRAND INC
NE NOBLE CORP (NEW)
FTREV FORTREA HOLDINGS INC.
Cytokinetics to Participate in September Investor Conferences
Cytokinetics to Participate in September Investor Conferences SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi’s 2025 BioPharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025 at 2:30 PM Eastern Time in Boston, MA.2025 Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 3, 2025 at 11:00 AM Eastern Time in Everett, MA.Cantor Global Healthcare Conference 2025:...
Cytokinetics Announces Five Presentations Related to Aficamten at the ...
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced ...
Cytokinetics Names Jim Daly to Board of Directors
Cytokinetics Names Jim Daly to Board of Directors SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors. “Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies,...
Ligand to Participate in September Investor Conferences
Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand ma...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 563...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 105,169 shares of common stock and 70,879 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 46 employees, whose employment commenced in July and August 2025 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the fir...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.